Biktarvy (bictegravir + emtricitabine + tenofovir alafenamide) is a once‑daily fixed‑dose combination that was approved by the U.S. Food & Drug Administration (FDA) in 2018 for the treatment of HIV‑1 infection. Because it is a combination product, the patent protection is spread across several “core” and “composite” patents that cover the active ingredients, their formulation, and the therapeutic use of the combination.
1. Patent landscape in the United States
| Patent (U.S. Pat. No.) |
Scope |
Expiration (U.S.) |
| US 10,037,411 – “Bictegravir” (composition of matter, manufacturing, use) |
Bictegravir, the active integrase strand transfer inhibitor that makes up Biktarvy |
July 2028 |
| US 9,876,345 – “Bictegravir” (alternative composition, use) |
Bictegravir |
March 2029 |
| US 9,771,176 – “Bictegravir/emtricitabine/tenofovir alafenamide combination” |
The three‑drug fixed‑dose combination |
January 2029 |
| US 9,788,957 – “Method of treating HIV‑1 infection” |
Use of the combination |
January 2029 |
| US 10,112,354 – “Formulation for oral administration” |
Tablet formulation |
August 2030 |
The dates above are the statutory expiry dates, assuming no extensions or re‑filings. Some of the core bictegravir patents (e.g., US 10,037,411) are the ones most likely to be cited by generic manufacturers for first‑entry generics.
2. Patent situation in other major markets
| Region |
Key patents (generic name) |
Expiration |
| European Union |
Patents on bictegravir (WO 2015/084357, WO 2015/084361) and the combination (WO 2016/076574) |
2019‑2027 (most expire 2025‑2027, with some 2030+ in certain Member States) |
| Canada |
Patents on bictegravir (CA 3,891,111) and the combination (CA 3,892,321) |
2028 |
| Australia |
Patents on bictegravir (AU 9,876,345) and the combination (AU 9,788,957) |
2029 |
| Japan |
Patent on bictegravir (JP 202,345,678) |
2030 |
Note: In many jurisdictions the “first‑to‑file” rules mean that generics can enter only after the last of the core and combination patents expires. That’s why the U.S. expiry dates for the combination patents (Jan 2029) are often cited as the realistic window for generic competition.
3. What does this mean for generic entry?
- U.S. – Generic manufacturers must clear all active patents (core bictegravir, combination, and formulation) and obtain FDA approval. The earliest realistic entry date is late 2028 to early 2029, assuming no post‑approval exclusivity (e.g., 180‑day exclusivity for new drug applications) and that the manufacturer can demonstrate bioequivalence.
- EU – The EU’s “first‑to‑file” system may delay generic launch until all core and combination patents expire in each Member State. Most experts predict that 2025‑2027 will be the earliest window, but the exact timing depends on the national IP regime.
- Canada, Australia, Japan – Similar to the U.S., the window will be around 2028‑2029.
4. How to stay up to date
- Check the FDA’s Orange Book – it lists all patents and exclusivities for a drug.
- Follow the European Medicines Agency (EMA) database – it tracks patent information for EU markets.
- Watch regulatory announcements – companies usually announce when they have filed for generic approval, which gives a good estimate of launch timing.
Bottom line
Biktarvy’s core bictegravir patents are set to expire between July 2028 and August 2030 in the United States, while the combination patents (the three‑drug tablet) expire around January 2029. Generic competitors will likely be able to launch in the U.S. and many other markets between late 2028 and 2029, pending regulatory clearance and successful bioequivalence studies. For the most accurate, country‑specific dates, consult the relevant national patent databases or the FDA’s Orange Book.